feed,title,long_url,short_url
Benzinga,"PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst",https://benzinga.com/analyst-ratings/analyst-color/22/09/29057281/pepgens-duchenne-candidate-has-potential-for-greater-exon-skipping-capabilities-at-,https://bit.ly/3dUfe9F
